EQS-Adhoc

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs

EQS-Ad-hoc: RELIEF THERAPEUTICS Holding AG / Key word(s): Patent Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs 24-Jan-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs

Notice of Allowance of Patent Application for a Non-Steroidal Anti-Inflammatory, Diclofenac Potassium, Strengthens Proprietary Position in U.S. until 2039

Geneva, Switzerland, January 24, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that its wholly owned subsidiary, APR Applied Pharma Research SA ("APR"), has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Application No. 16/713,052 entitled, "Ready to Use Diclofenac Packs."

Diclofenac potassium is an off-patent, potent non-steroidal anti-inflammatory drug ("NSAID") widely used therapeutically for inflammatory conditions and pain management. By applying the patented dynamic buffering technology ("DBT"), APR developed the first, and still the only, NSAID ever approved by the U.S. Food and Drug Administration ("FDA") for the treatment of acute migraine attacks in adults -- currently marketed as CAMBIA by Assertio Therapeutics Inc. in the U.S. and Miravo Healthcare (formerly Nuvo Pharmaceuticals Inc.) in Canada, under an exclusive, royalty bearing license agreement with APR.

DBT and CAMBIA are currently protected by a family of four patents listed in the FDA Orange Book, all expiring in 2026. CAMBIA is currently available in the form of a dry powder packed into a single dose sachet to be poured and dissolved in water before administration. APR, in order to offer a potential life cycle management option to its current commercial partners, has developed a liquid version of the same product packed into a portable stick pack in order to offer improved convenience to migraine patients; and this new dosage form is the subject matter of the new patent application just allowed by the USPTO.